Precision Business Insights
Portfolio

 

Research Reports

Middle East and Africa Preterm Labor Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

The Middle East and Africa Preterm Labor Treatment Market  : By Drugs (Tocolytic Drugs (Beta – Mimetic, Calcium Channel Blockers, NSAIDS), Corticosteroids, Magnesium Sulphate, Antibiotics, Others)), By Dosage Form (Tablets, Capsules, Injections), By End user (Hospitals, Pediatric and Neonatal Clinics, Nursing Homes, Pharmacy) and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

 

Market Dynamics: The Middle East and Africa Preterm Labor Treatment Market

 

Increase in premature birth cases and rapid increase birthrate are major driving factors of preterm labor treatment market. As per WHO statistics, every year 15Mn babies are born. Increase in technological advancements, increasing demand for preterm therapeutics and diagnostics, increase in support of government, increase in R&D investments by market players are expected to propel the growth of preterm labor treatment market. However, lack of awareness, stringent regulatory framework, high costs associated with the treatment will hamper the growth of preterm labor treatment market.

 

Market Scope: The Middle East and Africa Preterm Labor Treatment Market

The Middle East and Africa Preterm Labor Treatment market is segmented on the basis of drugs, dosage form, end user and geographical regions

Based on the drugs, The Middle East and Africa Preterm Labor Treatment market is segmented into the following

  • Tocolytic Drugs
  • Beta – Mimetic
  • Calcium Channel Blockers
  • NSAIDS
  • Corticosteroids
  • Magnesium Sulphate
  • Antibiotics
  • Others

 

Based on the Dosage form, The Middle East and Africa Preterm Labor Treatment market is segmented into the following

  • Tablets
  • Capsules
  • Injection

Based on End user, The Middle East and Africa Preterm Labor Treatment Market is segmented into the following:

  • Hospitals
  • Pediatric and Neonatal Clinics
  • Nursing Homes
  • Pharmacy

 

Country Analysis: The Middle East and Africa Preterm Labor Treatment Market

The Middle East and Africa Preterm Labor Treatment market is divided into Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of MEA. Growing incidence of the preterm birth, rise in government policies regarding the health of neonatal birth, pregnancy. However, lack of awareness, poor availability of infant and neonatal care, presence of few players restrains the growth in MEA region for preterm labor treatment market.

 

Competition Assessment: The Middle East and Africa Preterm Labor Treatment Market 

Key players’ profiles in the global The Middle East and Africa Preterm Labor Treatment Market include:

  • Pfizer (U.S.)
  • Novartis (Switzerland)
  • Merck & Co (U.S.)
  • Sanofi (France)
  • Johnson and Johnson (U.S.)
  • GlaxoSmithKline (UK)
  • AstraZeneca (UK)
  • Cipla (India)

 

Key Features of the Report:

 

  • The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 

  • Pfizer (U.S.)
  • Novartis (Switzerland)
  • Merck & Co (U.S.)
  • Sanofi (France)
  • Johnson and Johnson (U.S.)
  • GlaxoSmithKline (UK)
  • AstraZeneca (UK)
  • Cipla (India)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements